Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Combined With Cetuximab or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07432087Phase 3Not yet recruiting
- Start
- Feb 2026
- Primary completion
- Dec 2030
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 3 trial of camrelizumab in head and neck squamous cell carcinoma (HNSCC). Planned start Feb 2026; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07432087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07432087.